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Inhibition of Vascular c-Jun N-Terminal Kinase 2 Improves
Obesity-Induced Endothelial Dysfunction After Roux-en-Y Gastric
Bypass
Petia Doytcheva, PhD; Thomas B€achler, MD; Erika Tarasco, MSc; Vincenzo Marzolla, PhD; Michael Engeli, MSc;
Giovanni Pellegrini, DVM, PhD; Simona Stivala, PhD; Lucia Rohrer, PhD; Francesco Tona, MD, PhD; Giovanni G. Camici, PhD;
Paul M. Vanhoutte, MD, PhD; Christian M. Matter, MD; Thomas A. Lutz, DVM, PhD; Thomas F. L€uscher, MD; Elena Osto, MD, PhD
Background-—Roux-en-Y gastric bypass (RYGB) reduces obesity-associated comorbidities and cardiovascular mortality. RYGB
improves endothelial dysfunction, reducing c-Jun N-terminal kinase (JNK) vascular phosphorylation. JNK activation links obesity
with insulin resistance and endothelial dysfunction. Herein, we examined whether JNK1 or JNK2 mediates obesity-induced
endothelial dysfunction and if pharmacological JNK inhibition can mimic RYGB vascular beneﬁts.
Methods and Results-—After 7 weeks of a high-fat high-cholesterol diet, obese rats underwent RYGB or sham surgery; sham–
operated ad libitum–fed rats received, for 8 days, either the control peptide D-TAT or the JNK peptide inhibitor D-JNKi-1 (20 mg/kg
per day subcutaneous). JNK peptide inhibitor D-JNKi-1 treatment improved endothelial vasorelaxation in response to insulin and
glucagon-like peptide-1, as observed after RYGB. Obesity increased aortic phosphorylation of JNK2, but not of JNK1. RYGB and JNK
peptide inhibitor D-JNKi-1 treatment blunted aortic JNK2 phosphorylation via activation of glucagon-like peptide-1–mediated
signaling. The inhibitory phosphorylation of insulin receptor substrate-1 was reduced, whereas the protein kinase B/endothelial NO
synthase pathway was increased and oxidative stress was decreased, resulting in improved vascular NO bioavailability.
Conclusions-—Decreased aortic JNK2 phosphorylation after RYGB rapidly improves obesity-induced endothelial dysfunction.
Pharmacological JNK inhibition mimics the endothelial protective effects of RYGB. These ﬁndings highlight the therapeutic potential
of novel strategies targeting vascular JNK2 against the severe cardiovascular disease associated with obesity. ( J Am Heart Assoc.
2017;6:e006441. DOI: 10.1161/JAHA.117.006441.)
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O besity is associated with comorbidities, such as type 2diabetes mellitus and dyslipidemia, which increase
cardiovascular risk and mortality.1,2 In obesity, a systemic
chronic inﬂammation leads to oxidative stress, insulin resis-
tance, and endothelial dysfunction.3,4 Bariatric surgery, in
particular Roux-en-Y gastric bypass (RYGB), is the most
effective treatment against obesity.1 RYGB achieves sustained
weight loss and signiﬁcant long-term improvement of comor-
bidities; it also reduces cardiovascular morbidity and mortal-
ity.1,5,6 In addition to weight loss, surgery-speciﬁc changes of
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gut hormones, like glucagon-like peptide-1 (GLP-1) and bile
acids, may contribute to these improvements.7–9
The c-Jun N-terminal kinase (JNK) family of proteins links
obesity with insulin resistance and endothelial dysfunction. Of
the 3 known JNK isoforms, JNK1 and JNK2 are expressed
ubiquitously, whereas JNK3 expression is restricted to the
brain, heart, and testes.10 On activation, JNK suppresses
cellular insulin signaling via inhibitory phosphorylation of
insulin receptor substrate-1 (IRS-1) at Ser307 (Ser307–IRS-
1).11 In obese mice, whole-body deletion of JNK1 (JNK1/),
but not of JNK 2 (JNK2/), decreased total JNK activity in
liver, muscle, and adipose tissue, and reduced hepatic
Ser307–IRS-1 phosphorylation.12 This blunted weight gain
and improved glucose tolerance and insulin sensitivity.12 The
deletion of JNK2, performed either globally or speciﬁcally in
the liver, was also associated with the same favorable
metabolic proﬁle13,14 previously attributed to JNK1 deletion.
Hence, the in vivo tissue-speciﬁc interactions between the 2
JNK isoforms deserve further investigation under physiological
and pathological conditions.12–14
JNK is also critical in the pathophysiology of cardiovas-
cular disease. JNK2/ mice are protected from hyperc-
holesterolemia-induced oxidative stress, endothelial
dysfunction,15 and atherosclerosis.16 JNK2 may inhibit
endothelial NO synthase (eNOS) by phosphorylation at
Ser116 (Ser116-eNOS).17,18 Total JNK activation and
Ser307–IRS-1 phosphorylation, which are increased in the
aorta of spontaneously hypertensive rats, are associated
with vascular insulin resistance.19 Furthermore, in rat aortic
rings, the JNK inhibitor SP60012520 promotes vasodilation.21
However, SP600125 is not JNK speciﬁc and targets other
kinases.22,23 This drawback prompted the development of
more JNK-speciﬁc inhibitors (eg, the peptide inhibitor D-JNKi-
1 [D-JNK]), which more selectively blocks all JNK isoforms.24
Two-week treatment of obese diabetic db/db mice with the
L-enantiomer of D-JNK improves glucose tolerance and
insulin sensitivity, increases protein kinase B (Akt) activation,
and decreases Ser307–IRS-1 phosphorylation in liver, fat,
and muscle.25 Moreover, D-JNK treatment exerts neuropro-
tective effects in mouse models of cerebral ischemia, and
the compound is in preclinical trials.26
RYGB decreased total JNK activation and Ser307–IRS-1
inhibitory phosphorylation in the liver of type 2 diabetic rats
2 weeks after surgery.27 We previously showed, in obese rats,
a rapid improvement of endothelial function after RYGB.8 In
the aorta, RYGB decreased total JNK phosphorylation and
oxidative stress and activated the Akt/eNOS signaling
pathway, improving NO bioavailability, independent of body
weight loss.8 Therefore, the present study tested if pharma-
cological JNK inhibition in vivo in obese rats mimics the
protective endothelial effects of RYGB. Moreover, the speciﬁc
contribution of vascular JNK1 versus JNK2 in obesity-induced
endothelial dysfunction and in its improvement after RYGB
was investigated.
Methods
An expanded description of the methods is available in Data
S1.
The data, analytic methods, and study materials will be
made available on request of other researchers for purposes
of reproducing the results or replicating the procedure.
Antibodies and Reagents
The following commercially available antibodies were used:
JNK1/2 (R&D Systems, Minneapolis, MN); phosphorylated
JNK1/2 (Thr183/Tyr185) (Santa Cruz Biotechnology, Dallas,
TX); IRS-1 and phosphorylated IRS-1 (Ser307), Akt and
phosphorylated Akt (Ser473), protein kinase A (PKA) and
phosphorylated PKA (Thr197), cAMP response element bind-
ing protein and phosphorylated cAMP response element
Clinical Perspective
What Is New?
• In a rodent model of diet-induced obesity, c-Jun N-terminal
kinase 2 (JNK2), but not JNK1, phosphorylation was
speciﬁcally increased in the aorta.
• Roux-en-Y gastric bypass surgery restored obesity-induced
vascular dysfunction by blunting JNK2-vascular activation.
• Aortic inhibition of the JNK isoform 2 after Roux-en-Y gastric
bypass was associated with improved insulin and glucagon-
like peptide-1–mediated endothelium-dependent vasorelax-
ation as a result of preserved NO bioavailability and blunted
oxidative stress.
• In vivo treatment with 2 different JNK inhibitors improved
endothelium-mediated vasodilation and decreased aortic
JNK2 phosphorylation, thus mimicking the effect of Roux-en-
Y gastric bypass.
What Are the Clinical Implications?
• Our data suggest that novel drugs that selectively blunt
JNK2 activation without the downsides of available JNK
inhibitors may become a promising therapeutic option
against obesity-induced endothelial dysfunction and its
associated cardiovascular disease.
• It will be important to assess the vascular and metabolic
effects of a combination therapy of Roux-en-Y gastric
bypass and JNK inhibition.
• It is intriguing to hypothesize that, as a result of such dual
treatment, a higher increase in circulating glucagon-like
peptide-1 and/or in other gut hormones may synergistically
potentiate the beneﬁts observed in the present experi-
ments.
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binding protein (Ser133), protein kinase C (PKC) a/b and
phosphorylated PKCa/bII (Thr638/641), phosphorylated
PKCbII (Ser660), PKCd and phosphorylated PKCd (Thr505),
p38 mitogen-activated protein kinase (MAPK) and phospho-
rylated p38 MAPK (Thr180/Tyr182), p44/42 MAPK (extra-
cellular signal regulated kinase 1/2) and phosphorylated
p44/42 MAPK (extracellular signal regulated kinase 1/2)
(Thr202/Tyr204) (all from Cell Signaling, Danvers MA); PKCbII
(Thermo Fisher Scientiﬁc, Waltham, MA, United States);
eNOS/NOS type III and phosphorylated eNOS (Ser1177)
(BD Biosciences, San Jose, CA); phosphorylated eNOS Ser116
and GAPDH (both from Merck Millipore, Darmstadt, Germany);
and GLP-1 receptor (Abcam, Cambridge, UK).
Other items were purchased from supplies, as indicated:
high-fat high-cholesterol diet (Research Diets, New Brunswick,
NJ); SP600125 (Selleckchem, Houston, TX); selective JNK
inhibitor D-JNK (H-dqsrpvqpﬂnlttprkprpprrrqrrkkrG-NH2) and
control peptide D-TAT (H-pprrrqrrkkrG-NH2) (both from Pep-
scan, Lelystad, The Netherlands); dimethyl sulfoxide, nore-
pinephrine, Nx-nitro-L-arginine methyl ester, polyethylene
glycol–superoxide dismutase, sodium nitroprusside, dihy-
droethidium, and Hoechst 33258 (all from Sigma-Aldrich, St
Louis, MO); insulin (Humalog; Lilly, Indianapolis, IN); GLP-1
(7-36) amide (Bachem, Bubendorf, Switzerland); nicotinamide
ADP/reduced nicotinamide ADP (NADPH) assay kit (Abcam);
cyclic GMP ELISA kit (Cell Biolabs, San Diego, CA); active GLP-
1 kit (Meso Scale Discovery, Gaithersburg, MD); Microvette
with or without EDTA vacutainers (Sarstedt, N€umbrecht,
Germany); DPPIV inhibitor (Millipore, Darmstadt, Germany);
positive-charged slides, Superfrost Plus (Thermo Scientiﬁc,
Waltham, MA); RNeasy Mini Kit (Qiagen, Hilden, Germany);
Ready-To-Go You-Prime First-Strand Beads (GE Healthcare,
Little Chalfont, UK); and speciﬁc primers for quantitative
polymerase chain reaction (Microsynth, Balgach, Switzerland).
Animals and Experimental Procedures
Male Wistar rats were fed chow (lean non–operated on age-
matched controls, n=6) or a high-fat high-cholesterol diet to
induce obesity (60% kcal fat and 1.25% cholesterol; n=46) for
7 weeks before and after surgery.8 Obese rats were random-
ized to RYGB or sham surgery, and all procedures were
performed as described.8 Treatments started on the day after
surgery. A pilot (proof-of-concept) study and a main experiment
were performed with the 2 JNK inhibitors most commonly used
for in vivo investigations.20,24 In the pilot study, sham–operated
rats received SP600125, 40 mg/kg per day SC (SP600125,
n=8), or vehicle dimethyl sulfoxide sc (controlDMSO, n=6). The
main experiment compared RYGB (n=10) with sham–operated
ad libitum–fed rats treated for 8 days with either the selective
JNK inhibitor D-JNK (once-daily sc injection of 20 mg/kg per day;
H-dqsrpvqpﬂnlttprkprpprrrqrrkkrG-NH2; n=13) or an equimolar
dose (8.3 mg/kg) of the control peptide D-TAT sc (controlD-TAT;
H-pprrrqrrkkrG-NH2; n=9). Some controlD-TAT and D-JNK rats
were kept in metabolic cages to measure water intake and urine
excretion. The Cantonal Veterinary Ofﬁce of Zurich (Zurich,
Switzerland) approved all animal experiments (approval No.
060/2015_860).
Organ Chamber Experiments
The thoracic aorta was cut into 2- to 3-mm-long rings and
connected to an isometric force transducer (Multi-Myograph
610M; Danish Myo Technology A/S, Aarhus, Denmark),
suspended in an organ chamber ﬁlled with 6 mL Krebs-
Ringer bicarbonate solution (37°C, pH 7.4, 95% O2, 5% CO2).
Isometric tension was recorded continuously, as previously
described.8,15 After a 30-minute equilibration period, rings
were gradually stretched to reach the optimal point of their
length-tension curve, as determined by the contraction in
response to potassium chloride (100 mmol/L). During sub-
maximal contraction to norepinephrine (39106 mol/L),
concentration-relaxation curves were obtained in a cumula-
tive manner in response to insulin (1011 to 105 mol/L)
and GLP-1 (7-36) amide (1012 to 106 mol/L).28,29
Responses to insulin and GLP-1 were recorded in the
presence or absence of Nx-nitro-L-arginine methyl ester
(104 mol/L), a nonselective NO synthase inhibitor, or of the
free radical scavenger polyethylene glycol–superoxide dis-
mutase (150 U/mL). To study the direct vascular effects of
D-JNK, a subset of aortic rings were incubated ex vivo for
30 minutes with 5 lmol/L D-JNK before insulin or GLP-1.
The NO donor sodium nitroprusside (1010 to 105 mol/L)
was added to test endothelium-independent vasodilation.
Relaxations were expressed as a percentage of the precon-
traction with norepinephrine.
Western Blot Analysis
Frozen aortas were pulverized and dissolved in lysis buffer:
NaCl (120 mmol/L), Tris (50 mmol/L), NaF (20 mmol/L),
benzamidine (1 mmol/L), dithiothreitol (1 mmol/L), EDTA
(1 mmol/L), EGTA (6 mmol/L), sodium pyrophosphate
(15 mmol/L), p-nitrophenyl phosphate (30 mmol/L), phenyl-
methylsulfonyl ﬂuoride (0.1 mmol/L), leupeptin (0.8 lg/mL),
and NP-40 (1%). Analysis was performed with antibodies listed
in the Antibodies and Reagents subsection.
In Vitro Assays
NADPH oxidase activity, cGMP levels, and fasting plasma
concentrations of active GLP-1 were measured using
commercial kits listed in the Antibodies and Reagents
subsection.
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Statistical Analysis
Quantitative data are presented as meanSD or median with
interquartile range. Statistical analysis was conducted with
unpaired Student t test or by 1-way ANOVA, followed by the
Bonferroni post hoc test, as appropriate. Two-way ANOVA
with repeated measures was used to compare repeated
measurements in the same animals. Data were subjected to
the statistical analysis after a test of the data distribution
status using the Kolmogorov-Smirnov test. If the homogeneity
of variance assumption was violated, the nonparametric
Kruskal-Wallis test was used instead.
All tests were 2 sided, and statistical signiﬁcance was
accepted if the null hypothesis could be rejected at P<0.05.
All analyses were performed with GraphPad Prism Software
(version 7).
Results
In Vivo Pharmacological JNK Inhibition Improves
Obesity-Induced Endothelial Dysfunction Similar
to RYGB
Aortic relaxation in response to GLP-1 and insulin improved
similarly after D-JNK and RYGB when compared with obese
controlD-TAT animals (Figure 1A and 1B). Vasodilation was
abolished by preincubation with the eNOS inhibitor Nx-nitro-L-
arginine methyl ester, indicating an endothelial NO-dependent
mechanism (Figure S1A and S1B). Beforehand, we showed
that in lean non–operated age-matched and chow-fed male
Wistar rats, D-JNK did not alter GLP-1’s and insulin’s baseline
vasodilatory effects compared with vehicle-treated controls
(Figure S1C and S1D). Results after D-JNK treatment
strengthened the ﬁndings of the pilot experiment (Figure S1E
and S1F), in which rats receiving the JNK inhibitor SP600125
also improved vascular relaxation, although the effect was
less pronounced than after RYGB.
Vascular JNK Inhibition Improves Endothelial
Function in ControlD-TAT Rats
To test whether the improved relaxation seen in D-JNK rats
resulted from the direct vascular beneﬁts of JNK inhibition, a
subset of aortic rings isolated from D-JNK and controlD-TAT rats
were preincubated with 5 lmol/L D-JNK for 30 minutes
ex vivo21,24 before organ chamber experiments. Insulin- and
GLP-1–induced relaxations improved in controlD-TAT rings
treated ex vivo with D-JNK compared with untreated rings,
suggesting a direct aortic action of D-JNK (Figure 1C and 1D).
By contrast, ex vivo D-JNK preincubation did not further
ameliorate the response of aortas from the rats that had
received D-JNK for 8 days (Figure 1E and 1F).
In Vivo JNK Inhibition and RYGB Reduce Aortic
JNK2 Phosphorylation Induced by Obesity
Next, we assessed the speciﬁc contribution of the 2 vascular
JNK isoforms in obesity-induced endothelial dysfunction.
Phosphorylation of JNK2, but not of JNK1, increased in aortas
of obese controlD-TAT when compared with chow-fed lean D-TAT
rats (Figure 2A). Furthermore, aortic JNK2 phosphorylation was
signiﬁcantly decreased in RYGB and D-JNK–treated rats com-
pared with obese controlD-TAT rats, whereas JNK1 phosphory-
lation was not affected (Figure 2B). A similar result was
obtained after the pilot treatment with SP600125 (Figure S2A).
JNK Inhibition Restores Vascular Insulin- and GLP-
1–Dependent Akt/eNOS/NO Pathway Similar to
RYGB
The vascular Akt/eNOS signaling, which is activated by insulin
and GLP-18,28 and inhibited by JNK,11,17 was assessed by
Western blotting in aortic lysates. The JNK-dependent inhibitory
Ser307–IRS-1 phosphorylation decreased comparably after
RYGB and D-JNK (Figure 2C), whereas the activatory Akt-
Ser473 phosphorylation increased (Figure 2D). This led to
enhanced phosphorylation of the activatory eNOS-Ser1177
(Figure 3A), a favorable dimer/monomer ratio of eNOS (Fig-
ure 3B), which is essential for the proper coupling and function
of the enzyme.30,31 Finally, it augments NO production, as
assessed by increased aortic cGMP levels (Figure 3C). In vivo
SP600125 treatment also protected the insulin- and GLP-1–
dependent vascular signaling pathway, leading to preserved NO
bioavailability (Figure S2B through S2E). The phosphorylation of
Ser116 is a putative JNK2 target for the inhibition of eNOS.17,18
However, its assessment was inconclusive because of lack of
speciﬁcity of the commercially available anti–phosphorylated
Ser116-eNOS antibody in rat aortic tissue (Figure S3). Addi-
tional players able to modulate vascular insulin resistance,32–34
such as PKC (a/b, b II, and d; Figure S4A through S4C) and
extracellular signal regulated kinase 1/2 (p44 and p42;
Figure S4E), were assessed. No difference in phosphorylation
was observed between controls and rats after RYGB or JNK
inhibition, which further supports the role of reduced aortic
JNK2 phosphorylation as a crucial mediator of the vascular
beneﬁts of RYGB. Only the phosphorylation of p38 MAPK was
increased on JNK inhibition and unchanged in control and RYGB
rats (Figure S4D), which may be a potential off-target effect of
long-term systemic in vivo D-JNK treatment.
JNK Inhibition Reduces Vascular Oxidative Stress
Similar to RYGB
JNK enhances vascular oxidative stress, which, in turn,
reduces NO bioavailability and leads to endothelial
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dysfunction.35,36 Decreased oxidative stress after RYGB
protects endothelial function.8 Therefore, it was further
assessed if in vivo JNK inhibition also mimics the effect of
RYGB on the vascular reduction-oxidation balance. Preincu-
bation with the free radical scavenger superoxide dismutase
improved relaxation in response to insulin and GLP-1 only in
aortic rings of controlD-TAT rats. No further improvements were
observed in RYGB- and D-JNK–treated rats, which suggests
markedly reduced oxidative stress in these contexts (Fig-
ure 3D and 3E). Concurrent with this notion, dihydroethidium
staining of aortic sections showed decreased superoxide
anion (O2 ) levels after RYGB and after D-JNK treatment
(Figure 3F). NADPH oxidase activity, which contributes to the
generation of O2 ,
35 was also signiﬁcantly decreased in the
B
D
F
A
C
E
Figure 1. Cumulative concentration-response curves of aortic rings isolated 8 days after Roux-en-Y gastric bypass (RYGB) or
sham surgery/start of treatment after submaximal contraction to norepinephrine in response to glucagon-like peptide-1 (GLP-1;
A) and insulin (B) in RYGB rats, controlD-TAT rats, and rats treated with the peptide inhibitor D-JNKi-1 (D-JNK rats) (n=7–13 per
group). Ex vivo relaxation of aortic rings with or without 30 minutes ex vivo preincubation with 5 lmol/L D-JNK. Concentration-
response curves after submaximal contraction to norepinephrine in response to GLP-1 (C) and insulin (D) in controlD-TAT rats and
to GLP-1 (E) and insulin (F) in D-JNK rats (n=3–6 per group). Results are evaluated by 2-way repeated measures ANOVA and
Bonferroni post hoc test. Data are shown as meanSD. *P<0.05, ***P<0.001 for RYGB vs controlD-TAT; °°°P<0.001 for
controlD-TAT vs D-JNK;
##P<0.01, ###P<0.001 for controlD-TAT vs D-TAT preincubated 30 minutes ex vivo with 5 lmol/L D-JNK.
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aortas of both RYGB and D-JNK rats, thus contributing to
preserved NO bioavailability (Figure 4A). Similar results were
obtained after SP600125 treatment (Figure S5A and S5B).
GLP-1 Contributes to Vascular JNK2 Inhibition
After RYGB
Increased circulating GLP-1 contributes to the beneﬁcial
cardiovascular effects of RYGB.8,9 GLP-1–dependent PKA
activation inhibits JNK1 and JNK2 in various tissues,
including the endothelium,34,37 where it also activates the
Akt/eNOS pathway.38,39 In line with our previous results,8
fasting plasma GLP-1 levels were increased after RYGB
(Figure 4B). Surprisingly, D-JNK treatment also increased
GLP-1 levels compared with controlD-TAT rats, although to a
lesser extent than RYGB (Figure 4B). By contrast, SP600125
did not affect circulating GLP-1 levels (Figure S5C). The
aortic expression of the GLP-1 receptor was up-regulated in
RYGB and D-JNK rats. This was accompanied downstream by
enhanced phosphorylation of the PKA isoform C-a at Thr197
and of the cAMP response element binding protein at
Ser133 (Figure 4C through 4E), which lie upstream of JNK1
and JNK2 inhibition.34,37 To further ascertain the role of GLP-
1 in modulating JNK2 phosphorylation after RYGB, we
analyzed aortas from our previous study, in which sham–
operated on rats were treated with the GLP-1 analogue
liraglutide and RYGB rats received the GLP-1 receptor
antagonist exendin-9 for 8 days after surgery.8 JNK2 phos-
phorylation remained high in RYGB rats on GLP-1 receptor
blockade, whereas liraglutide treatment in sham–operated
on rats decreased JNK2 phosphorylation. JNK1 phosphory-
lation was unchanged in all groups (Figure 5A). These results
suggest that vascular JNK2 inactivation may contribute to
the GLP-1–dependent improvement of endothelial
B
JNK 2
JNK 1
JNK 2
JNK 1
p-Thr183/
Tyr185
total
A
JNK 2
JNK 1
JNK 2
JNK 1
p-Thr183/
Tyr185
total
p-IRS-1 Ser307
total IRS-1
total Akt
p-Akt Ser473
C
D
Figure 2. (A), c-Jun N-terminal kinase (JNK) 1 and JNK2 phosphorylation (46 and 55 kDa, respectively) in the aortas of lean chow-fed D-TAT vs
obese controlD-TAT rats (determined by unpaired t test). Phosphorylation of aortic JNK1 and JNK2 (B), insulin receptor substrate-1 (IRS-1) Ser307
(C), and protein kinase B (Akt) Ser473 (D) in controlD-TAT, Roux-en-Y gastric bypass (RYGB), and peptide inhibitor D-JNKi-1 (D-JNK) rats 8 days
after surgery/start of treatment. Representative Western blots and densitometric quantiﬁcations are shown (determined by 1-way ANOVA and
Bonferroni post hoc test; n=4–13 per group). Results are shown as meanSD. p indicates phosphorylated. ¢P<0.05 for chow-fed control peptide
D-TAT vs controlD-TAT, *P<0.05 for RYGB vs controlD-TAT, °P<0.05 for controlD-TAT vs D-JNK.
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dysfunction seen after RYGB.8 In line with previous results,8
RYGB reduced food intake and body weight (Figure 5B and
5C). D-JNK treatment affected food intake and body weight
similar to RYGB (Figure 5B and 5C), whereas SP600125 had
no effect on these 2 parameters compared with its vehicle
(Figure S6A and S6B). Non–operated chow-fed rats treated
for 8 days with D-TAT and D-JNK did not show differences in
body weight between the 2 groups (Figure S6C). This
difference between the 2 JNK inhibitors prompted additional
investigations to assess potential toxicity associated with
the pharmacological treatment (Figure S7), as described in
Data S1.
Discussion
JNKs link metabolic to cardiovascular disease.8,12,14,15,17,18
The novel ﬁndings of this study show that RYGB via GLP-1–
dependent signaling improves obesity-induced endothelial
dysfunction by speciﬁc inhibition of aortic JNK2 phosphory-
lation. We provide the following key observations: (1) obesity
speciﬁcally increased JNK2, but not JNK1, phosphorylation in
the aorta; (2) RYGB improved endothelial function via a
speciﬁc decrease of aortic JNK2 phosphorylation; (3) in vivo
pharmacological JNK inhibition rapidly mimics this beneﬁcial
vascular effect; and (4) on lower JNK2 phosphorylation, the
A
total eNOS
eNOS dimer
eNOS monomer
p-eNOS-Ser1177
F
B
C
E
D
+ SOD 150 U/mL
+ SOD 150 U/mL
RYGB D-JNK
controlsD-TAT
Figure 3. (A) Endothelial NO synthase (eNOS) Ser1177 phosphorylation (p-eNOS); and eNOS dimerization (B). Representative Western
blots and densitometric quantiﬁcations are shown (determined by 1-way ANOVA and Bonferroni post hoc test; n=6–13 per group). (C), In
vitro quantiﬁcation of cGMP levels in controlD-TAT, Roux-en-Y gastric bypass (RYGB), and peptide inhibitor D-JNKi-1 (D-JNK) rats 8 days after
surgery/start of treatment (determined by Kruskal-Wallis test and Dunn multiple comparison test; n=6–13 per group). Effect of
preincubation with 150 U/mL of polyethylene glycol–superoxide dismutase (SOD) on the endothelium-dependent relaxation to glucagon-
like peptide-1 (GLP-1); (D) and insulin (E) in the same experimental groups (no differences, determined by 2-way repeated measures ANOVA
and Bonferroni post hoc test; n=3–9 per group). F, Representative pictures of dihydroethidium ﬂuorescent staining of superoxide anions
and relative quantiﬁcation in aortas isolated 8 days after surgery from controlD-TAT, RYGB, and D-JNK rats (determined by 1-way ANOVA and
Bonferroni post hoc test; n=7–10 per group). Results are shown as meanSD (A, B, and F) or medianinterquartile range (C). *P<0.05,
**P<0.01 for RYGB vs controlD-TAT; °P<0.05, °°P<0.01, °°°P<0.001 for controlD-TAT vs D-JNK.
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insulin- and GLP-1–dependent Akt/eNOS signaling was
restored, oxidative stress was decreased, and aortic NO
bioavailability was preserved. The major results and proposed
underlying mechanisms are summarized in Figure 6.
RYGB Reduces Aortic JNK2 Phosphorylation
Induced by Obesity and Protects Endothelial
Function
Studies using tissue-speciﬁc gene targeting in mice pointed
initially to JNK112,14 and later to JNK213 as pivotal players in
the pathophysiological characteristics of obesity and type 2
diabetes mellitus. Hence, the role of the 2 isoforms in the
overall JNK activity in metabolic disease is yet unclear.
JNK2/ mice were protected against hypercholesterolemia-
induced endothelial dysfunction15 and atheroma formation,16
which may suggest a speciﬁc contribution of JNK isoform 2 in
the pathophysiological characteristics of atherosclerotic dis-
ease. We and others described also the association between
total JNK activation and endothelial dysfunction induced by
obesity8,40 and type 2 diabetes mellitus41; however, the role
of JNK1 versus JNK2 has not yet been elucidated in this
context.
Our study shows that in obesity, enhanced aortic-speciﬁc
JNK2 phosphorylation impairs the insulin/IRS-1– and GLP-1/
GLP-1 receptor–dependent Akt/eNOS/NO pathway, leading
to endothelial dysfunction, whereas JNK1 phosphorylation
remains unchanged. Indeed, RYGB reduces JNK2 hyperphos-
phorylation and, thus, preserves the common insulin- and
GLP-1–mediated Akt/eNOS-dependent NO production and
restores endothelial function.29 RYGB-mediated speciﬁc JNK2
inhibition was associated with decreased aortic Ser307–IRS-1
A
p-PKA Thr197
total PKA
p-CREB Ser133
total CREB
C
GLP-1 
receptor
GAPDH
D E
B
Figure 4. (A), Reduced nicotinamide ADP (NADPH) oxidase activity in aortas (determined by 1-way ANOVA and Bonferroni post hoc test; n=6–
13 per group). (B), Fasting plasma glucagon-like peptide-1 (GLP-1) levels in controlD-TAT, Roux-en-Y gastric bypass (RYGB), and peptide inhibitor
D-JNKi-1 (D-JNK) rats 8 days after surgery/start of treatment (determined by Kruskal-Wallis test and Dunn multiple comparison test; n=6–13 per
group). Aortic GLP-1 receptor expression (C) and phosphorylation of protein kinase A (p-PKA) C-a Thr197 (D) and cAMP response element
binding protein (p-CREB) Ser133 (E) in the same groups. Representative Western blots and densitometric quantiﬁcations are shown (determined
by 1-way ANOVA and Bonferroni post hoc test; n=6–13 per group). Results are shown as meanSD (A and C-E) or medianinterquartile range
(B). *P<0.05, **P<0.01 for RYGB vs all other groups; °P<0.05 for controlD-TAT vs D-JNK.
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phosphorylation. To date, the inhibitory Ser307–IRS-1 phos-
phorylation has been linked to total JNK activity in the context
of hepatic insulin resistance.12 Only one study in sponta-
neously hypertensive rats linked Ser307–IRS-1 phosphoryla-
tion to aortic insulin resistance as a result of total JNK
increased activity, with no further investigations on JNK
isoform speciﬁcity.19
In Vivo Inhibition of JNK Mimics the Endothelial
Protective Effects of RYGB
In vivo treatment with 2 different JNK inhibitors improved
endothelium-mediated vasodilation and decreased aortic JNK2
phosphorylation. Activation of the intracellular Akt/eNOS
signaling led to higher NO production, thus mimicking the
effect of RYGB. D-JNK treatment decreased weight loss and
food intake equally to RYGB; however, body weight loss per se
is not sufﬁcient to improve endothelial function, as previously
shown in sham–operated rats whose body weight loss was
matched to RYGB by food restriction.8 We observed that in rats
that were body weight matched to RYGB rats, endothelial
dysfunction persisted and was associated with increased total
JNK phosphorylation at the aortic level.8 Furthermore, the pilot
study showed that the favorable impact of SP600125 on
endothelial function can also be achieved in the absence of
body weight loss or reduced eating, suggesting a speciﬁc
vascular beneﬁt on pharmacological JNK inhibition. In addition,
short-term ex vivo D-JNK treatment improved vasodilation of
aortas of controlD-TAT rats but had no incremental beneﬁt in
animals receiving long-term in vivo D-JNK treatment. These
BA
JNK 2
JNK 1
p-Thr183/
Tyr185
total
JNK 2
JNK 1
C
Figure 5. (A), Aortic c-Jun N-terminal kinase (JNK) 1 and JNK2 phosphorylation in sham–operated on rats treated with vehicle (controls)
or liraglutide, 0.2 mg/kg BID sc (controls-lira), and Roux-en-Y gastric bypass–operated on rats treated with vehicle (RYGB) or exendin-9,
10 lg/kg per hour (RYGB-exe9), for 8 days. Tissues were taken from rats of a previous study on day 8 after surgery or after the start of
treatment, respectively8 (determined by 1-way ANOVA and Bonferroni post hoc test; n=8–13 per group). Cumulative 24-hour food intake
(determined by 2-way ANOVA and Bonferroni post hoc test; n=8–13 per group; (B) and body weight (C) of controlD-TAT, RYGB, and peptide
inhibitor D-JNKi-1 (D-JNK) rats before and after surgery and start of treatment (day 0) (no differences, determined by 2-way repeated
measures ANOVA and Bonferroni post hoc test; n=8–13 per group). Results are shown as meanSD. p indicates phosphorylated.
*P<0.05 and **P<0.01 for RYGB vs controls or RYGB-exe9; ***P<0.001 for RYGB vs controlD-TAT;
&&&P<0.001 for RYGB vs D-JNK; °°°D-JNK
vs controlD-TAT.
DOI: 10.1161/JAHA.117.006441 Journal of the American Heart Association 9
JNK2 Inhibition and Endothelial Function After RYGB Doytcheva et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on N
ovem
ber 28, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
ﬁndings support a JNK inhibitory effect directly exerted in the
aortas to complement other systemic beneﬁcial metabolic
effects of in vivo D-JNK treatment.25,42
JNKs promote reactive oxygen species production, which
impairs NO bioavailability and leads to endothelial dysfunc-
tion.15,36 In agreement with our previous ﬁndings,8 the
preincubation of aortic rings with the radical scavenger
superoxide dismutase improved insulin- and GLP-1–mediated
relaxations of aortas in controlD-TAT rats but not in RYGB and
D-JNK treated rats. This result conﬁrms the reduction of
vascular oxidative stress, as shown by the reduced O2 levels
and NADPH oxidase activity,35 in the aortas of RYGB and D-
JNK rats. In microvascular endothelial cells, NADPH-depen-
dent increase of reactive oxygen species after hypoxia/
reoxygenation was blunted by SP600125 and by dominant-
negative JNK1, whereas the role of JNK2 in that condition had
not been investigated in detail.43 Our ﬁndings suggest that in
the aorta, obesity may speciﬁcally induce NADPH oxidase via
JNK2, rather than JNK1, activation.
GLP-1–Dependent Inhibition of Aortic JNK2
Restores Endothelial Function After RYGB
Finally, the present study focused on the role of
upstream GLP-1–dependent molecular pathways in medi-
ating aortic JNK2 inactivation after RYGB. In line with our
previous results,8 fasting plasma GLP-1 levels and aortic
GLP-1 receptor expression were increased after RYGB.
GLP-1–dependent aortic PKA Thr197 and cAMP response
element binding protein Ser133 activatory phosphoryla-
tions were increased and accompanied by downstream
JNK2 inhibition, thus strengthening the mechanistic link
between increased GLP-1 signaling after RYGB and
aortic JNK2 inhibition. This notion was supported by the
fact that in vivo GLP-1 receptor antagonism with exendin-
9 in RYGB rats blocked the JNK2 inhibition achieved
by RYGB, whereas GLP-1 agonism with liraglutide tended
to mimic the beneﬁt of RYGB in obese sham–operated on
rats.
p-JNK2
GLP-1• RYGB
• D-JNK
p-PKA
insulin
NO
Endothelial-dependent relaxaon
NADPH oxidase
O2-
p-IRS-1 ser307
• D-JNK
• SP600125
Endothelial 
Cell
Vascular lumen
Ser1177
eNOS
dimerizaon
P
Ser473
Akt
P
GLP-1 receptor
Figure 6. Proposed mechanism(s) underlying the improvement of endothelium-dependent vasodilation
after Roux-en-Y gastric bypass (RYGB). Higher circulating glucagon-like peptide-1 (GLP-1) after RYGB
activates the endothelial GLP-1 receptor and downstream protein kinase A (PKA), which inhibits c-Jun
N-terminal kinase (JNK) 2. JNK2 directly inhibits endothelial NO synthase (eNOS) and insulin receptor
substrate-1 (IRS-1) in the insulin signaling pathway; PKA and IRS-1 lead to protein kinase B (Akt) activation,
which then directly stimulates eNOS. This, in turn, leads to improved NO bioavailability and vasodilation. In
parallel, JNK2 inactivation inhibits reduced nicotinamide ADP (NADPH) oxidase activity and decreases the
levels of superoxide anions, which further contributes to preserved NO bioavailability and vasodilation.
These beneﬁcial effects of RYGB were mimicked by in vivo pharmacological JNK inhibition. Blue and red
arrows indicate experimentally observed activation and inactivation, respectively, of proposed downstream
mediators. D-JNK indicates peptide inhibitor D-JNKi-1; and p, phosphorylated.
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Interestingly, systemic administration of D-JNK also
increased circulating GLP-1 levels; this was not observed
with SP600125, possibly because of its lower potency and
speciﬁcity.23 Peripheral GLP-1 is secreted from intestinal
endocrine cells in response to nutrients44 and insulin.45
Therefore, JNK inhibition in the small intestine may inﬂuence
GLP-1 secretion through the insulin signaling. Hence, sys-
temic JNK inhibition may improve endothelium-mediated
vasodilation through a direct inactivation of vascular JNK2,
and indirectly through increased GLP-1 signaling, which may
further contribute to blunt JNK2 and to activate eNOS in
aortas, as summarized in Figure 6. In future studies, it would,
therefore, be important to assess the vascular and metabolic
effects of a combination therapy between RYGB and JNK
inhibition in comparison to the single treatment reported in
the present study. It is intriguing to hypothesize that, as a
result of such dual treatment, higher increases in circulating
GLP-1 and/or in other gut hormones may synergistically
potentiate the beneﬁts observed in the present experiments.
Study Limitations
Reduced JNK2-dependent inhibitory phosphorylated Ser116-
eNOS may have contributed to the observed beneﬁts of RYGB
and JNK inhibition,17,18 but lack of speciﬁcity of the commer-
cially available antibodies in the rat aorta did not allow a
satisfactory assessment of this putative JNK2 target.
SP600125 inhibits multiple other kinases besides JNK,23
which limits its clinical application. On the other hand, D-JNK
treatment, despite a high JNK speciﬁcity,24 may induce renal
toxicity, in particular in obese animals, which seems attribu-
table to its carrier peptide, D-TAT, and thus is independent of
the D-JNK inhibitory activity, as previously shown.46 Indeed, we
observed proximal tubule injury in the carrier peptide–treated
controlD-TAT and in D-JNK rats. In a previous study, despite
improved glucose control, albuminuria worsened after in vivo
treatment with the peptide JNK inhibitor in diabetic db/db
mice42 by an effect possibly linked to the D-TAT carrier
peptide–induced kidney toxicity, independent of the metabolic
beneﬁts of JNK inhibition.42,46 In our study, SP600125
treatment was not associated with kidney injury, further
supporting the presence of JNK-independent cytotoxicity (ie,
toxicity related to the D-TAT carrier peptide).46 Last, in D-JNK
treated rats, aortic phosphorylation of p38 MAPK was
increased, in contrast to previous in vitro studies testing
D-JNK speciﬁcity.26,47 Although potential off-target effects of
long-term systemic in vivo D-JNK administration cannot be
excluded, in our setting, this treatment led to overall improved
aortic Akt/eNOS signaling and NO bioavailability.
Overall, our data suggest that novel drugs, able to
selectively blunt JNK2 activation without the downsides of
available JNK inhibitors, may become a promising therapeutic
option against obesity-induced endothelial dysfunction and its
associated cardiovascular disease.
Conclusions
Obesity-induced activation of vascular JNK2 and the associ-
ated endothelial dysfunction were reversed by RYGB, through
GLP-1–dependent signaling. These beneﬁcial effects of RYGB
were mimicked by in vivo pharmacological JNK inhibition,
highlighting the potential therapeutic relevance of novel
strategies targeting vascular JNK2 against the severe cardio-
vascular disease associated with obesity.
Acknowledgments
We thank Sara Gobbato for technical help and Amy Taheri for a
critical revision of the article.
Author Contributions
The contributions to the article were as follows: study design:
Osto and Lutz; study conduct, data collection, and analysis:
Osto, Doytcheva, B€achler, Tarasco, Marzolla, Engeli, Pellegrini,
Stivala, and Rohrer; writing: Osto, Lutz, Doytcheva, Marzolla,
Tona, Camici, Vanhoutte, Matter, and L€uscher. All authors had
full access and take full responsibility for the integrity of the
data and the accuracy of the data analysis.
Sources of Funding
This work was supported, in part, by the University of Zurich
Forschungskredit (FK-85701-02-01 to Osto and FK-15-051 to
Doytcheva); the Swiss National Science Foundation Ambi-
zione Grant (PZOOP3_161S0S/1 to Osto); the Swiss Card-
Onco-Grant, Alfred and Annemarie von Sick Grant (Lutz and
Osto); and the Swiss Heart Foundation (Lutz and Osto).
Disclosures
None.
References
1. Poirier P, Cornier MA, Mazzone T, Stiles S, Cummings S, Klein S, McCullough
PA, Ren Fielding C, Franklin BA; American Heart Association Obesity
Committee of the Council on Nutrition, Physical Activity, and Metabolism.
Bariatric surgery and cardiovascular risk factors: a scientiﬁc statement from
the American Heart Association. Circulation. 2011;123:1683–1701.
2. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200
countries from 1975 to 2014: a pooled analysis of 1698 population-based
measurement studieswith19.2millionparticipants.Lancet. 2016;387:1377–1396.
3. Mauricio MD, Aldasoro M, Ortega J, Vila JM. Endothelial dysfunction in morbid
obesity. Curr Pharm Des. 2013;19:5718–5729.
4. Bays HE, Toth PP, Kris-Etherton PM, Abate N, Aronne LJ, Brown WV, Gonzalez-
Campoy JM, Jones SR, Kumar R, La Forge R, Samuel VT. Obesity, adiposity, and
DOI: 10.1161/JAHA.117.006441 Journal of the American Heart Association 11
JNK2 Inhibition and Endothelial Function After RYGB Doytcheva et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on N
ovem
ber 28, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
dyslipidemia: a consensus statement from the National Lipid Association. J
Clin Lipidol. 2013;7:304–383.
5. Adams TD, Davidson LE, Litwin SE, Kolotkin RL, LaMonte MJ, Pendleton RC,
Strong MB, Vinik R, Wanner NA, Hopkins PN, Gress RE, Walker JM, Cloward TV,
Nuttall RT, Hammoud A, Greenwood JL, Crosby RD, McKinlay R, Simper SC,
Smith SC, Hunt SC. Health beneﬁts of gastric bypass surgery after 6 years.
JAMA. 2012;308:1122–1131.
6. Brethauer SA, Heneghan HM, Eldar S, Gatmaitan P, Huang H, Kashyap S,
Gornik HL, Kirwan JP, Schauer PR. Early effects of gastric bypass on
endothelial function, inﬂammation, and cardiovascular risk in obese patients.
Surg Endosc. 2011;25:2650–2659.
7. Laferrere B, Reilly D, Arias S, Swerdlow N, Gorroochurn P, Bawa B, Bose M,
Teixeira J, Stevens RD, Wenner BR, Bain JR, Muehlbauer MJ, Haqq A, Lien L,
Shah SH, Svetkey LP, Newgard CB. Differential metabolic impact of gastric
bypass surgery versus dietary intervention in obese diabetic subjects despite
identical weight loss. Sci Transl Med. 2011;3:80re82.
8. Osto E, Doytcheva P, Corteville C, Bueter M, Dorig C, Stivala S, Buhmann H,
Colin S, Rohrer L, Hasballa R, Tailleux A, Wolfrum C, Tona F, Manz J, Vetter D,
Spliethoff K, Vanhoutte PM, Landmesser U, Pattou F, Staels B, Matter CM, Lutz
TA, Luscher TF. Rapid and body weight-independent improvement of
endothelial and high-density lipoprotein function after Roux-en-Y gastric
bypass: role of glucagon-like peptide-1. Circulation. 2015;131:871–881.
9. Seeley RJ, Chambers AP, Sandoval DA. The role of gut adaptation in the potent
effects of multiple bariatric surgeries on obesity and diabetes. Cell Metab.
2015;21:369–378.
10. Hotamisligil GS. Role of endoplasmic reticulum stress and c-Jun NH2-terminal
kinase pathways in inﬂammation and origin of obesity and diabetes. Diabetes.
2005;54(suppl 2):S73–S78.
11. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal
kinase promotes insulin resistance during association with insulin receptor
substrate-1 and phosphorylation of Ser(307). J Biol Chem. 2000;275:9047–
9054.
12. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M,
Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature.
2002;420:333–336.
13. Vernia S, Cavanagh-Kyros J, Garcia-Haro L, Sabio G, Barrett T, Jung DY, Kim JK,
Xu J, Shulha HP, Garber M, Gao G, Davis RJ. The PPARalpha-FGF21 hormone
axis contributes to metabolic regulation by the hepatic JNK signaling pathway.
Cell Metab. 2014;20:512–525.
14. Tuncman G, Hirosumi J, Solinas G, Chang L, Karin M, Hotamisligil GS.
Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and
insulin resistance. Proc Natl Acad Sci USA. 2006;103:10741–10746.
15. Osto E, Matter CM, Kouroedov A, Malinski T, Bachschmid M, Camici GG, Kilic
U, Stallmach T, Boren J, Iliceto S, Luscher TF, Cosentino F. c-Jun N-terminal
kinase 2 deﬁciency protects against hypercholesterolemia-induced endothelial
dysfunction and oxidative stress. Circulation. 2008;118:2073–2080.
16. Ricci R, Sumara G, Sumara I, Rozenberg I, Kurrer M, Akhmedov A, Hersberger
M, Eriksson U, Eberli FR, Becher B, Boren J, Chen M, Cybulsky MI, Moore KJ,
Freeman MW, Wagner EF, Matter CM, Luscher TF. Requirement of JNK2 for
scavenger receptor A-mediated foam cell formation in atherogenesis. Science.
2004;306:1558–1561.
17. Park JH, Park M, Byun CJ, Jo I. c-Jun N-terminal kinase 2 phosphorylates
endothelial nitric oxide synthase at serine 116 and regulates nitric oxide
production. Biochem Biophys Res Commun. 2012;417:340–345.
18. Cho DH, Park JH, Joo Lee E, Jong Won K, Lee SH, Kim YH, Hwang S, Ja Kwon K,
Young Shin C, Song KH, Jo I, Han SH. Valproic acid increases NO production
via the SH-PTP1-CDK5-eNOS-Ser(116) signaling cascade in endothelial cells
and mice. Free Radic Biol Med. 2014;76:96–106.
19. Sugita M, Sugita H, Kaneki M. Increased insulin receptor substrate 1 serine
phosphorylation and stress-activated protein kinase/c-Jun N-terminal kinase
activation associated with vascular insulin resistance in spontaneously
hypertensive rats. Hypertension. 2004;44:484–489.
20. Bennett BL, Sasaki DT, Murray BW, O’Leary EC, Sakata ST, Xu W, Leisten JC,
Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW.
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl
Acad Sci USA. 2001;98:13681–13686.
21. Zhou MS, Schulman IH, Chadipiralla K, Raij L. Role of c-Jun N-terminal kinase in
the regulation of vascular tone. J Cardiovasc Pharmacol Ther. 2010;15:78–83.
22. Bain J, McLauchlan H, Elliott M, Cohen P. The speciﬁcities of protein kinase
inhibitors: an update. Biochem J. 2003;371:199–204.
23. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur
JS, Alessi DR, Cohen P. The selectivity of protein kinase inhibitors: a further
update. Biochem J. 2007;408:297–315.
24. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. Cell-permeable peptide
inhibitors of JNK: novel blockers of beta-cell death. Diabetes. 2001;50:77–82.
25. Kaneto H, Nakatani Y, Miyatsuka T, Kawamori D, Matsuoka TA, Matsuhisa M,
Kajimoto Y, Ichijo H, Yamasaki Y, Hori M. Possible novel therapy for diabetes
with cell-permeable JNK-inhibitory peptide. Nat Med. 2004;10:1128–1132.
26. Borsello T, Clarke PG, Hirt L, Vercelli A, RepiciM, Schorderet DF, Bogousslavsky J,
Bonny C. A peptide inhibitor of c-Jun N-terminal kinase protects against
excitotoxicity and cerebral ischemia. Nat Med. 2003;9:1180–1186.
27. He B, Piao D, Yu C, Wang Y, Han P. Amelioration in hepatic insulin sensitivity
by reduced hepatic lipid accumulation at short-term after Roux-en-Y gastric
bypass surgery in type 2 diabetic rats. Obes Surg. 2013;23:2033–2041.
28. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon
MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways
related to production of nitric oxide in human vascular endothelial cells.
Circulation. 2000;101:1539–1545.
29. Ding L, Zhang J. Glucagon-like peptide-1 activates endothelial nitric oxide
synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin.
2012;33:75–81.
30. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular
disease: from marvel to menace. Circulation. 2006;113:1708–1714.
31. Farah C, Kleindienst A, Bolea G, Meyer G, Gayrard S, Geny B, Obert P, Cazorla
O, Tanguy S, Reboul C. Exercise-induced cardioprotection: a role for eNOS
uncoupling and NO metabolites. Basic Res Cardiol. 2013;108:389.
32. Montecucco F, Steffens S, Mach F. Insulin resistance: a proinﬂammatory state
mediated by lipid-induced signaling dysfunction and involved in atherosclerotic
plaque instability. Mediators Inﬂamm. 2008;2008:767623.
33. Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in
insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 2007;3:46–56.
34. Erdogdu O, Eriksson L, Xu H, Sjoholm A, Zhang Q, Nystrom T. Exendin-4
protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK,
and JNK pathways. J Mol Endocrinol. 2013;50:229–241.
35. Salisbury D, Bronas U. Reactive oxygen and nitrogen species: impact on
endothelial dysfunction. Nurs Res. 2015;64:53–66.
36. Son Y, Kim S, Chung HT, Pae HO. Reactive oxygen species in the activation of
MAP kinases. Methods Enzymol. 2013;528:27–48.
37. Ferdaoussi M, Abdelli S, Yang JY, Cornu M, Niederhauser G, Favre D, Widmann
C, Regazzi R, Thorens B, Waeber G, Abderrahmani A. Exendin-4 protects beta-
cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun
NH2-terminal kinase pathway. Diabetes. 2008;57:1205–1215.
38. Han L, Yu Y, Sun X, Wang B. Exendin-4 directly improves endothelial
dysfunction in isolated aortas from obese rats through the CAMP or AMPK-
eNOS pathways. Diabetes Res Clin Pract. 2012;97:453–460.
39. Erdogdu O, Nathanson D, Sjoholm A, Nystrom T, Zhang Q. Exendin-4
stimulates proliferation of human coronary artery endothelial cells through
eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor.
Mol Cell Endocrinol. 2010;325:26–35.
40. Farb MG, Karki S, Park SY, Saggese SM, Carmine B, Hess DT, Apovian C,
Fetterman JL, Breton-Romero R, Hamburg NM, Fuster JJ, Zuriaga MA, Walsh K,
Gokce N. WNT5A-JNK regulation of vascular insulin resistance in human
obesity. Vasc Med. 2016;21:489–496.
41. Breton-Romero R, Feng B, Holbrook M, Farb MG, Fetterman JL, Linder EA, Berk
BD, Masaki N, Weisbrod RM, Inagaki E, Gokce N, Fuster JJ, Walsh K, Hamburg
NM. Endothelial dysfunction in human diabetes is mediated by Wnt5a-JNK
signaling. Arterioscler Thromb Vasc Biol. 2016;36:561–569.
42. Ijaz A, Tejada T, Catanuto P, Xia X, Elliot SJ, Lenz O, Jauregui A, Saenz MO,
Molano RD, Pileggi A, Ricordi C, Fornoni A. Inhibition of c-Jun N-terminal kinase
improves insulin sensitivity but worsens albuminuria in experimental diabetes.
Kidney Int. 2009;75:381–388.
43. Yu G, Peng T, Feng Q, Tyml K. Abrupt reoxygenation of microvascular
endothelial cells after hypoxia activates ERK1/2 and JNK1, leading to NADPH
oxidase-dependent oxidant production. Microcirculation. 2007;14:125–136.
44. Spreckley E, Murphy KG. The L-cell in nutritional sensing and the regulation of
appetite. Front Nutr. 2015;2:23.
45. Lim GE, Huang GJ, Flora N, LeRoith D, Rhodes CJ, Brubaker PL. Insulin
regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell.
Endocrinology. 2009;150:580–591.
46. Cardozo AK, Buchillier V, Mathieu M, Chen J, Ortis F, Ladriere L, Allaman-Pillet
N, Poirot O, Kellenberger S, Beckmann JS, Eizirik DL, Bonny C, Maurer F. Cell-
permeable peptides induce dose- and length-dependent cytotoxic effects.
Biochem Biophys Acta. 2007;1768:2222–2234.
47. Repici M, Mare L, Colombo A, Ploia C, Sclip A, Bonny C, Nicod P, Salmona M,
Borsello T. c-Jun N-terminal kinase binding domain-dependent phosphorylation
of mitogen-activated protein kinase kinase 4 and mitogen-activated protein
kinase kinase 7 and balancing cross-talk between c-Jun N-terminal kinase and
extracellular signal-regulated kinase pathways in cortical neurons. Neuro-
science. 2009;159:94–103.
DOI: 10.1161/JAHA.117.006441 Journal of the American Heart Association 12
JNK2 Inhibition and Endothelial Function After RYGB Doytcheva et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on N
ovem
ber 28, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Supplemental Material 
 by guest on N
ovem
ber 28, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Data S1
Tissue harvesting and blood collection 
Rats were sacrificed eight days after surgery and start of treatment. Rats were 
fasted overnight and sacrificed at the beginning of the light cycle by isoflurane 
anesthesia followed by heart exsanguination. For plasma analyses, blood collected in 
Microvette EDTA vacutainers was supplemented with a DPPIV inhibitor; for serum 
analyses, blood was collected in Microvette vacutainers. After centrifugation, plasma 
or serum were stored at -80°C. Organs were harvested within 30 minute after 
exsanguination. The thoracic aorta was placed immediately in cold modified Krebs-
Ringer bicarbonate solution (pH 7.4, 37°C, 95% O2, 5% CO2) of the following 
composition (mmol/L): NaCl (118.6), KCl (4.7), CaCl2 (2.5), KH2PO4 (1.2), MgSO4 
(1.2), NaHCO3 (25.1), glucose (11.1), and calcium EDTA (0.026). The aorta was 
cleaned from adhering connective tissue and was either snap-frozen in liquid 
nitrogen and stored at -80°C or used immediately for ex vivo organ chamber 
experiments. 
Dihydroethidium staining on rat aortae 
Frozen 10 µm sections from aortae were cut with a Leica CM3050S cryostat 
and placed on positive-charged slides Superfrost Plus. Dihydroethidium (DHE) was 
prepared as stock solution in DMSO, diluted in deoxygenated PBS (final 
concentration 5 µM), and applied to frozen sections for 30 min at 37°C. Nuclei were 
counterstained with Hoechst 33258 (final concentration 1µg/ml). Slides were 
coverslipped and images taken on a SP8 microscope (10x/0.30 objective; Leica, 
Solms, Germany), and quantified (ImageJ, NIH). DHE fluorescence was calculated 
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by subtracting the auto-fluorescence signal (green channel) from the DHE signal (red
channel), and normalized to the total fluorescent area. 
qPCR analysis 
Expression of kidney injury molecule-1 (KIM-1) and lipocalin-2 (NGAL) was 
analyzed by qPCR of snap-frozen kidney tissue. RNA was isolated from frozen 
kidneys with a RNaeasy Mini Kit and reverse transcribed with a Ready-To-Go You-
Prime First-Strand Beads. Rat-specific primers were used for KIM-1 (forward: 
GTGGGTCACCCTGTCACAAT, reverse: ATGTTGTATCGACCGCTGCT) and NGAL 
(forward: GATGAACTGAAGGAGCGATTC, reverse:
TCGGTGGGAACAGAGAAAAC). CT results were normalized to GAPDH CT. 
Histological analysis 
Representative samples of aorta, liver, pancreas, kidneys, thyroid glands, 
inguinal white adipose tissue and interscapular brown adipose tissue were fixed in 
10% neutral buffered formalin and embedded in paraffin. Sections (3-5 µm) were 
prepared, mounted on glass slides, deparaffinised in xylene, rehydrated through 
graded alcohols and stained with haematoxylin and eosin (H&E) for the histological 
examination. All slides were scanned using digital slide scanner NanoZoomer-XR 
C12000 (Hamamatsu, Hamamatsu City, Japan) and images were taken using NDP-
view2 viewing software (Hamamatsu). 
Renal injury, characterized by tubular degeneration and regeneration and interstitial 
inflammation, was assessed by light microscopy in a blinded fashion (by G.P.). A 
semi-quantitative scoring of 0-5 was employed, based on the proportion of affected 
tubules: 0, none; 1, <10% (slight injury); 2, 11-25% (mild); 3, 26-45% (moderate); 4, 
46-75% (marked); and 5, >75% (severe).
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Supplemental Results 
JNK2 inhibition after in vivo SP600125 treatment induces protective vascular 
effects similar to RYGB 
In the pilot experiment, eight-day treatment of DIO sham-operated ad libitum-
fed rats with SP600125 increased endothelium-mediated relaxation in response to 
GLP-1 and insulin similar to RYGB, although the effect was less pronounced than in 
RYGB rats (Fig. S1E-F). In vivo SP600125 treatment decreased aortic JNK2 
phosphorylation compared to controlsDMSO rats, while JNK1 phosphorylation was not 
affected (Fig. S2A). JNK2 inhibition was followed by decreased IRS-1 Ser307 and 
increased Akt Ser473 phosphorylation and higher eNOS dimerization similar to 
RYGB and D-JNK treatment (Fig. S2B-E). Additionally, in vivo SP600125 
treatment also decreased aortic superoxide anion levels and NADPH activity 
comparable to RYGB surgery (Fig. S5A-B). SP600125 did not affect circulating 
GLP-1 levels (Fig. S5C). These results support a direct role of vascular JNK2 
inactivation in lowering oxidative stress and activating Akt/eNOS signaling pathways 
to improve endothelial function after RYGB, and prompted us to perform the main 
experiment using the more specific JNK inhibitor D-JNK. 
Aortic eNOS Ser116 phosphorylation 
It has been published that JNK2 directly inhibits eNOS by Ser116 
phosphorylation in studies using bovine aortic endothelial cells 1 and mouse aortae 2. 
Unfortunately, we could not detect eNOS Ser116 phosphorylation in rat aorta with the 
same anti-human Ser116 antibody used in previous publications 1, 2. This antibody, 
which is the only commercially available anti-phospho-Ser 116 eNOS, showed bands 
between 100 kDa and 130 kDa, but not at 140 kDa, which is the expected molecular 
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weight of eNOS. In contrast, total eNOS was detected at 140 kDa (Fig. S3). The
eNOS Ser116 antibody has not been validated in rat tissue before (personal 
communication; Merck Millipore) and the only available results had been obtained 
with bovine aortic endothelial cells 1. One study assessed eNOS Ser116 in mice 
aortae, but representative images for total and phosphorylated eNOS did not report 
the molecular weight references to rule out an unspecific binding 2. A sequence 
alignment of the human and rat immunogenic regions used for this antibody showed 
sub-optimal homology, suggesting limited reactivity (personal communication; Merck 
Millipore). Therefore, it is possible that the antibody is not suitable to detect eNOS 
Ser116 phosphorylation specifically in rat tissue. 
D-TAT carrier peptide-dependent kidney toxicity
D-JNK treatment affected food intake and body weight similar to RYGB
(Fig.6B-C), while SP600125 or D-JNK in chow-fed lean rats (Fig. S6A-C) had no 
effect. This prompted us to investigate organ toxicity as a potential cause of weight 
loss after chronic D-JNK treatment in obese rats. Circulating markers of liver and 
kidney damage were assessed (urea, creatinine, cystatin C, transferrin, albumin, 
alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase). Only 
creatinine and cystatin C levels were significantly elevated in the D-JNK group, 
suggesting potential kidney toxicity (Fig. S6D-E). Furthermore, histological 
analysis indicated tubular degeneration and necrosis, accompanied by tubular 
regeneration and interstitial, predominantly lymphohistiocytic cell infiltration (Fig.
S7A-B). Renal injury also occurred in controlsD-TAT rats but was more moderate 
(approximately 40% tubules affected) compared to D-JNK-treated rats (> 80%). 
These histological changes were accompanied by impaired kidney function in 
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controlsD-TAT and D-JNK animals, with increased urinary excretion and a presumably
compensatory higher water intake (Fig. S7C-F). There was no statistically 
significant difference in urine excretion and water intake between controlsD-TAT and D-
JNK animals. Gene expression analysis of acute kidney injury markers showed 
increased kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated 
lipocalin/lipocalin 2 (NGAL) in obese rats upon D-JNK and D-TAT treatment (Fig. 
S7G-H). A slight increase of these kidney injury markers was also observed in 
chow-fed D-TAT- and D-JNK-treated animals while SP600125 did not affect KIM-1 
and NGAL expression (Fig. S7G-H). The analyses of aorta, liver, pancreas, 
thyroid glands, white and brown adipose tissue from controlsD-TAT and D-JNK rats did 
not show biochemical or histological signs of toxicity (data not shown), suggesting a 
kidney-specific effect. To our knowledge, this is the first study clearly showing in vivo 
D-JNK toxicity in the kidney. Published data on D-JNK pharmacokinetics after a
single intra-peritoneal injection in mice reported a higher accumulation of D-JNK in 
the filter organs (kidney and liver) and in urine for up to one week, suggesting that D-
JNK excretion is almost exclusively urinary 3. In D-JNK, the active JNK inhibitory 
peptide is conjugated to a commonly used cell-penetrating oligo-peptide, the HIV-1 
TAT protein, which functions as a carrier 4. It has been reported that various cell-
permeable peptides, including D-TAT oligo-peptides such as D-JNK, induce in vitro 
length-dependent cytotoxic effects irrespective of their sequence 5. Therefore, the 
observed kidney damage was likely due to intrinsic cytotoxicity of the D-TAT carrier 
peptide independent of the D-JNK inhibitory activity 5. This would explain why renal 
toxicity, which was observed in both controlsD-TAT and D-JNK rats, was more 
pronounced in the D-JNK rats because of the peptide length. No toxicity was 
observed with SP600125, which supports the independence of toxicity from the JNK 
inhibitory activity of D-JNK. 
 by guest on N
ovem
ber 28, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
6 
Supplemental Figures 
Figure S1
Concentration–response curves after 30 minute pre-incubation with 10-4 mol/L 
endothelial NO synthase inhibitor, L-NAME and submaximal contraction to NE in 
response to (A) GLP-1 and (B) insulin in controlsD-TAT, RYGB, and D-JNK rats (n=3 
per group). Concentration–response curves after submaximal contraction to NE in 
response to (C) GLP-1 and (D) insulin in non-operated, chow-fed rats treated with D-
TAT or D-JNK for eight days (n=2-4 per group). Relaxations in response to (E) GLP-1 
and (F) insulin in RYGB, controlsDMSO, and SP600125 rats (*, **, *** p<0.05, p<0.01, 
p<0.001 RYGB vs. controlsDMSO, &&, &&& p<0.01, p<0.001 RYGB vs. SP600125, as 
determined by two-way repeated measures ANOVA and Bonferroni post hoc test; 
n=5-10 per group). Results are shown as mean ± SD. 
B         Fig. S1A
+ L-NAME 10-4 mol/L + L-NAME 10-4 mol/L
C D
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Figure S2 
Aortic (A) JNK1 and JNK2 phosphorylation, (B) IRS-1 Ser307, (C) Akt Ser473, (D) 
eNOS Ser1177 phosphorylation and (E) eNOS dimerization in controlsDMSO, RYGB, 
and SP600125 rats eight days after surgery/start of treatment. Representative 
Western blots and densitometric quantifications are shown (*, **, *** p<0.05, p<0.01, 
p<0.001 RYGB vs. controlsDMSO, §, §§ p<0.05, p<0.01 controlsDMSO vs. SP600125, as 
determined by one-way ANOVA and Bonferroni post hoc test; n=5-11 per group). 
Results are shown as mean ± SD. 
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Figure S3 
Western blot analysis of (A) eNOS Ser116 phosphorylation and (B) total eNOS 
(molecular weight of 140 kDa) in the same aortic lysates from controlsD-TAT, RYGB, 
and D-JNK rats. Representative pictures are shown. 
Fig. S3
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Figure S4 
Western blot analysis of phosphorylation of (A) PKC alpha/beta Thr638/641, (B) 
PKCβII Ser 660, (C) PKCδ Thr 505, (D) p38 MAPK Thr180/Tyr182, (E) ERK1/2 (44 
and 42 KD, respectively) in controlsD-TAT, RYGB, and D-JNK rats eight days after 
surgery/start of treatment. Representative Western blots and densitometric 
quantifications are shown (* p<0.05 D-JNK vs RYGB and controlsD-TAT, as 
determined by one-way ANOVA and Bonferroni post hoc test; n=7 per group). 
Results are shown as mean ± SD. 
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Figure S5 
(A) In vitro DHE fluorescent staining of anion superoxide and relative quantification in
aortae isolated from controlsDMSO, RYGB and SP600125 rats eight days after 
surgery/start of treatment. Representative pictures are shown. (B) In vitro NADPH 
oxidase activity in aortae isolated eight days after surgery (* p<0.05 RYGB vs. all 
other groups, § p<0.05 controlsDMSO vs. SP600125, as determined by one-way 
ANOVA and Bonferroni post hoc test; n=7-9 per group). (C) Fasting plasma GLP-1 
levels (* p<0.05 RYGB vs. all other groups, as determined by Kruskal-Wallis test and 
Dunn’s Multiple Comparison test; n=6-16 per group).  Results are shown as mean ± 
SD except in Figure S5C where results are presented as median ± IQR. 
Fig. S5
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Figure S6 
(A) Cumulative 24-hour food intake (*, **, *** p<0.05, p<0.01, p<0.001 RYGB vs.
controlsD-TAT, controlsDMSO, as determined by two-way ANOVA and Bonferroni post 
hoc test; n=8-13 per group) and (B) body weight of controlsDMSO, RYGB and 
SP600125 rats before and after surgery and start of treatment (day 0) (*, ** p<0.05, 
p<0.01 RYGB vs. controlsD-TAT, controlsDMSO, as determined by two-way repeated 
measures ANOVA and Bonferroni post hoc test; n=8-13 per group). (C) Body weight 
(n=4 per group) in non-operated, chow-fed rats treated with D-TAT or D-JNK for eight 
days (no differences, as determined by two-way repeated measures ANOVA and 
Bonferroni post hoc test; n=2-4 per group). (D) Serum creatinine and (E) plasma 
cystatin C levels in controlsD-TAT, RYGB, and D-JNK rats eight days after surgery/start 
of treatment (** p<0.01 RYGB vs. D-JNK, ° p<0.05 controlsD-TAT vs. D-JNK, as 
determined by Kruskal-Wallis test and Dunn’s Multiple Comparison test; n=6-8 per 
group). Results are shown as mean ± SD except in Figure S6D-E where results 
are presented as median ± IQR. 
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Figure S7 
Histological analysis by hematoxylin and eosin (H&E) staining of kidney from (A) a D-
JNK and (B) a controlsD-TAT rat euthanized eight days after sham surgery/start of 
treatment. Cumulative 24-hour urine excretion in (C) controlsD-TAT rats and (D) D-JNK 
rats, and cumulative 24-hour water intake in (E) controlsD-TAT rats and (F) D-JNK rats 
1 day before and 7 and 8 days after surgery and start of treatment (#, ##, ### 
p<0.05, p<0.01, p<0.001 Day -1 vs. Day 7 and Day 8, as determined by one-way 
ANOVA and Bonferroni post hoc test;  n=6 per group). qPCR analysis of kidney 
expression of (G) kidney injury molecule-1(KIM-1) and (H) neutrophil gelatinase-
associated lipocalin (NGAL) eight days after surgery and start of treatment (°, °°° 
p<0.05, p<0.001 D-JNK vs. all other groups, as determined by Kruskal-Wallis test 
and Dunn’s Multiple Comparison test; n=4-7 per group). Results are shown as mean 
± SD except in Figure S7G-H where results are presented as median ± IQR. 
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